Hsbc Holdings PLC Has $6.86 Million Position in QIAGEN N.V. $QGEN

Key Points

• Hsbc Holdings PLC has significantly reduced its stake in QIAGEN N.V. by 57.7%, now owning only 173,189 shares worth approximately $6.86 million.
• Several institutional investors have adjusted their positions, with 70.00% of QIAGEN's shares currently owned by hedge funds and other institutional investors.
• QIAGEN recently reported earnings of $0.60 per share, matching analysts' expectations, and set guidance for future earnings, reflecting a 7.7% year-over-year revenue increase.

Hsbc Holdings PLC reduced its position in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 57.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 173,189 shares of the company's stock after selling 236,245 shares during the quarter. Hsbc Holdings PLC owned 0.08% of QIAGEN worth $6,857,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new stake in QIAGEN during the 4th quarter valued at $202,000. GAMMA Investing LLC grew its holdings in shares of QIAGEN by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after acquiring an additional 1,425 shares in the last quarter. Cetera Investment Advisers increased its stake in shares of QIAGEN by 23.2% in the first quarter. Cetera Investment Advisers now owns 13,917 shares of the company's stock worth $551,000 after acquiring an additional 2,620 shares during the last quarter. Avantax Advisory Services Inc. increased its stake in shares of QIAGEN by 30.2% in the first quarter. Avantax Advisory Services Inc. now owns 9,869 shares of the company's stock worth $396,000 after acquiring an additional 2,290 shares during the last quarter. Finally, Federated Hermes Inc. acquired a new position in shares of QIAGEN in the first quarter worth $150,000. 70.00% of the stock is owned by institutional investors and hedge funds.

QIAGEN Price Performance

Shares of NYSE QGEN traded down $1.92 during mid-day trading on Thursday, hitting $46.07. 5,362,485 shares of the stock were exchanged, compared to its average volume of 1,298,769. The company has a market cap of $10.24 billion, a P/E ratio of 27.22, a PEG ratio of 2.52 and a beta of 0.64. The stock's fifty day simple moving average is $48.71 and its two-hundred day simple moving average is $44.06. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. QIAGEN N.V. has a twelve month low of $37.63 and a twelve month high of $51.88.

QIAGEN (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting the consensus estimate of $0.60. The company had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The company's revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the business posted $0.55 earnings per share. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, analysts forecast that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Bank of America increased their target price on shares of QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Wall Street Zen cut shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. Barclays started coverage on shares of QIAGEN in a report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target for the company. UBS Group upped their price target on shares of QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Finally, Cowen restated a "hold" rating on shares of QIAGEN in a report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, QIAGEN presently has an average rating of "Hold" and an average price target of $49.69.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.